Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26429578 | 0.84 | CTSK (0.46) | CTSKKCNA3CKS1BSKP1SKP2 | |
| SCHEMBL16340873 | 0.82 | PDE10A (0.40) | KMT2A | |
| SCHEMBL16003828 | 0.77 | CTSK (0.48) | CTSKKCNA3CKS1BSKP1SKP2 | |
| SCHEMBL16003606 | 0.76 | PDE10A (0.58) | KCNA3CKS1BSKP1SKP2PARP1 | |
| SCHEMBL2801999 | 0.73 | SUV39H2 (0.52) | CTSKCKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL1592531 | 0.71 | CKS1B (0.60) | KCNA3CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL12291575 | 0.71 | CKS1B (0.49) | CTSKKCNA3CKS1BSKP1SKP2 | |
| SCHEMBL11985018 | 0.71 | KCNA3 (0.50) | CTSKKCNA3CKS1BSKP1SKP2 | |
| SCHEMBL16682477 | 0.71 | CKS1B (0.51) | CTSKKCNA3CKS1BSKP1SKP2 | |
| SCHEMBL30670681 | 0.70 | KMT2A (0.45) | CTSKCKS1BSKP1SKP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777000-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-9458157-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9453015-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9440970-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150166536-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150132327-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-8980888-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980889-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| WO-2014133046-A1 | NOVEL PYRAZOLE DERIVATIVE | 持田製薬株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166536-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CTSK 1320/4885KCNA3 2382/4885CKS1B 2123/4885 |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CTSK 1320/4885KCNA3 2382/4885CKS1B 2123/4885 |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CTSK 1320/4885KCNA3 2382/4885CKS1B 2123/4885 |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CTSK 1320/4885KCNA3 2382/4885CKS1B 2123/4885 |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CTSK 1320/4885KCNA3 2382/4885CKS1B 2123/4885 |
| US-20150132327-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CTSK 1320/4885KCNA3 2382/4885CKS1B 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.